Related references
Note: Only part of the references are listed.Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
Philippe Guilpain et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists
Lila Bouadma et al.
INTENSIVE CARE MEDICINE (2020)
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Sara Monti et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD
Carina Mihai et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis
Ennio Giulio Favalli et al.
JOURNAL OF RHEUMATOLOGY (2020)
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York
Rebecca Haberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management
Marco Matucci-Cerinic et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Muriel Elhai et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Share Paper
